Net income declined to €537 million or €0.48 per share from €630 million or €0.56 per share last year.
Excluding one-time items, adjusted basic earning per share was €0.58 compared with €0.65 a year ago.
Revenue for the quarter was down at €6.056 billion compared with €6 billion in the previous year.
On a comparable basis, revenue grew by 10.8%, excluding the discontinued rapid COVID-19 antigen-test business, particularly driven by growth in the Varian and the Imaging segments.
For the fiscal year 2024, the company expects comparable revenue to grow 4.5% – 6.5% year on year.
Adjusted basic earnings per share for the year is expected to be between €2.10 and €2.30.
